Nefiracetam
Modify Date: 2025-08-20 11:07:56
Nefiracetam structure
|
Common Name | Nefiracetam | ||
|---|---|---|---|---|
| CAS Number | 77191-36-7 | Molecular Weight | 246.305 | |
| Density | 1.2±0.1 g/cm3 | Boiling Point | 458.5±33.0 °C at 760 mmHg | |
| Molecular Formula | C14H18N2O2 | Melting Point | 151-155°C | |
| MSDS | Chinese USA | Flash Point | 231.1±25.4 °C | |
| Symbol |
GHS07 |
Signal Word | Warning | |
Use of NefiracetamNefiracetam is a GABAergic, cholinergic, and monoaminergic neuronal systems enhancer for Ro 5-4864-induced convulsions.Target: GABA ReceptorNefiracetam induces a short-term depression of ACh-evoked currents at submicromolar concentrations (0.01-0.1 μM) and a long-term enhancement of the currents at micromolar concentrations (1-10 μM). Nefiracetam interacts with PKA and PKC pathways, which may explain a cellular mechanism for the action of cognition-enhancing agents. Lower (submicromolar) concentrations of the nootropic Nefiracetam reduces ACh-evoked currents to 30% (0.01 μM) and 38% (0.1 μM) of control after a 10-minute treatment [1].Nefiracetam administered orally inhibits Ro 5-4864-induced convulsions in EL mice. Nefiracetam also efficiently inhibits Ro 5-4864-induced convulsions in DDY mice at doses higher than 10 mg/kg [2]. Nefiracetam administered daily 1 hour before each training session facilitates the acquisition process of the avoidance response [3]. |
| Name | N-(2,6-Dimethylphenyl)-2-(2-oxopyrrolidin-1-yl)acetamide |
|---|---|
| Synonym | More Synonyms |
| Description | Nefiracetam is a GABAergic, cholinergic, and monoaminergic neuronal systems enhancer for Ro 5-4864-induced convulsions.Target: GABA ReceptorNefiracetam induces a short-term depression of ACh-evoked currents at submicromolar concentrations (0.01-0.1 μM) and a long-term enhancement of the currents at micromolar concentrations (1-10 μM). Nefiracetam interacts with PKA and PKC pathways, which may explain a cellular mechanism for the action of cognition-enhancing agents. Lower (submicromolar) concentrations of the nootropic Nefiracetam reduces ACh-evoked currents to 30% (0.01 μM) and 38% (0.1 μM) of control after a 10-minute treatment [1].Nefiracetam administered orally inhibits Ro 5-4864-induced convulsions in EL mice. Nefiracetam also efficiently inhibits Ro 5-4864-induced convulsions in DDY mice at doses higher than 10 mg/kg [2]. Nefiracetam administered daily 1 hour before each training session facilitates the acquisition process of the avoidance response [3]. |
|---|---|
| Related Catalog | |
| References |
| Density | 1.2±0.1 g/cm3 |
|---|---|
| Boiling Point | 458.5±33.0 °C at 760 mmHg |
| Melting Point | 151-155°C |
| Molecular Formula | C14H18N2O2 |
| Molecular Weight | 246.305 |
| Flash Point | 231.1±25.4 °C |
| Exact Mass | 246.136826 |
| PSA | 49.41000 |
| LogP | 1.53 |
| Vapour Pressure | 0.0±1.1 mmHg at 25°C |
| Index of Refraction | 1.594 |
| Storage condition | Store at RT |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
| Symbol |
GHS07 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H302-H319 |
| Precautionary Statements | P305 + P351 + P338 |
| Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Gloves |
| Hazard Codes | Xn |
| Risk Phrases | R22 |
| RIDADR | NONH for all modes of transport |
| RTECS | UX9655650 |
| HS Code | 2933790090 |
|
~87%
Nefiracetam CAS#:77191-36-7 |
| Literature: Daiichi Pharmaceutical Co., Ltd. Patent: US5461157 A1, 1995 ; |
| Precursor 2 | |
|---|---|
| DownStream 0 | |
| HS Code | 2933790090 |
|---|---|
| Summary | 2933790090. other lactams. VAT:17.0%. Tax rebate rate:9.0%. . MFN tariff:9.0%. General tariff:20.0% |
|
Investigation on urinary proteins and renal mRNA expression in canine renal papillary necrosis induced by nefiracetam.
Arch. Toxicol. 79(9) , 500-7, (2005) The occurrence of renal papillary necrosis (RPN), seen only in dogs after repeated oral administration of nefiracetam, a neurotransmission enhancer, at a relatively high dose, is because of inhibition... |
|
|
Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.
Neuroscience 160(2) , 484-91, (2009) The cholinergic and glutamatergic systems are known to be downregulated in the brain of Alzheimer's disease patients. Galantamine and nefiracetam have been shown to potentiate the phasic activity of n... |
|
|
Anticonvulsant properties of the novel nootropic agent nefiracetam in seizure models of mice and rats.
Epilepsia 46(6) , 811-8, (2005) Nefiracetam (NEF) is a novel pyrrolidone-type nootropic agent, and it has been reported to possess various pharmacologic effects as well as cognition-enhancing effects. The present study focused on th... |
| N-(2,6-dimethylphenyl)-2-(2-oxopyrrolidin-1-yl)acetamide |
| Nefiracetam |
| MFCD00209882 |
| Dmmpa |
| 2-(2-Oxo-1-pyrrolidinyl)-N-(2,6-dimethylphenyl)acetamide |
| N-(2,6-Dimethylphenyl)-2-(2-oxo-1-pyrrolidinyl)acetamide |
| 1-Pyrrolidineacetamide, N-(2,6-dimethylphenyl)-2-oxo- |